Wnt/β-catenin pathway activation is associated with Oct4/Nanog-mediated epithelial-mesenchymal transition (EMT) and drug resistance, and silencing β-catenin abrogates Oct4/Nanog’s effects on NSCLC cells, effectively reversing the drug resistance [35]. The gene discussed is POU5F1; the disease is non-small cell lung carcinoma.